Preliminary experience with triamcinolone acetonide during pregnancy

Area of Science:

• Obstetrics and Gynecology
• Pulmonology
• Pharmacology

Background:

• Inhaled corticosteroids are recommended for asthma in pregnancy, but triamcinolone acetonide data is lacking.
• Asthma management during pregnancy requires careful consideration of maternal and fetal outcomes.

Purpose of the Study:

• To evaluate the safety and efficacy of inhaled triamcinolone acetonide for asthma treatment in pregnant women.
• To compare outcomes with inhaled beclomethasone dipropionate and oral theophylline.

Main Methods:

• Retrospective cohort study in a tertiary care urban hospital.
• Comparison of birth weights and asthma exacerbation hospitalization rates.
• Analysis of pregnant women receiving inhaled triamcinolone acetonide, beclomethasone dipropionate, or theophylline.

Main Results:

• Triamcinolone acetonide group showed a trend towards higher mean birth weights, though not statistically significant.
• Significantly fewer triamcinolone acetonide users (33%) were hospitalized for asthma exacerbations compared to beclomethasone users (79%; P < 0.05).
• Hospitalization rates for triamcinolone acetonide were comparable to theophylline (28%; P = NS).

Conclusions:

• Inhaled triamcinolone acetonide appears to be at least as efficacious as beclomethasone for treating asthma during pregnancy.
• Preliminary data suggest potential benefits in reducing asthma exacerbation hospitalizations.
• Further clinical trials are recommended to confirm the safety and efficacy of inhaled triamcinolone acetonide in pregnancy.